Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.
The U.S. Health Resources and Services Administration posted Alcon’s public notice about the refunds to 340B covered entities yesterday. Alcon said its recalculated 340B prices
are due to restated pricing data it submitted to the Centers for Medicare & Medicaid Services.
Alcon said it “will be working through an external third party to issue refunds to each affected covered entity that is entitled to a refund. Refunds will be issued either to a covered entity’s validated wholesaler pharmacy account when one can be identified, or a check will be issued to the respective covered entities whose wholesaler account(s) cannot be identified.” The notice includes contact information for entities that believe they are due a refund but have not been contacted by April 30.
HRSA last year posted 34 notices by drug manufacturers to covered entities about refunds for charges above 340B ceiling prices, more than double the 16 posted in 2021 and 15 in 2020. There were seven in 2019. The notices have become more common since January 2019 when manufacturers first became subject to civil monetary penalties for knowing and intentional 340B overcharges.
